Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Accumulated Expenses (2016 - 2025)

Conmed's Accumulated Expenses history spans 16 years, with the latest figure at $82.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 25.66% year-over-year to $82.1 million; the TTM value through Dec 2025 reached $82.1 million, up 25.66%, while the annual FY2025 figure was $82.1 million, 25.66% up from the prior year.
  • Accumulated Expenses reached $82.1 million in Q4 2025 per CNMD's latest filing, up from $76.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $82.1 million in Q4 2025 to a low of $40.9 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $58.0 million, with a median of $55.2 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: surged 33.59% in 2021, then decreased 9.51% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $60.5 million in 2021, then dropped by 9.51% to $54.7 million in 2022, then rose by 28.02% to $70.1 million in 2023, then dropped by 6.71% to $65.4 million in 2024, then grew by 25.66% to $82.1 million in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Accumulated Expenses are $82.1 million (Q4 2025), $76.1 million (Q3 2025), and $67.9 million (Q2 2025).